Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling

Molecular Oncology

Volumn 6, Issue 3, 2012, Pages 276-283

  Nam, Sangkil ^a   Scuto, Anna ^a   Yang, Fan ^a   Chen, WenYong ^a   Park, Sungman ^b   Yoo, Hwa Seung ^c   Konig, Heiko ^d   Bhatia, Ravi ^a   Cheng, Xinlai ^e   Merz, Karl Heinz ^e   Eisenbrand, Gerhard ^e   Jove, Richard ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c Daejeon University   (South Korea)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

Author keywords

Apoptosis; CML; Indirubin; SFKs; Stat5

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CD34 ANTIGEN; COMPOUND E 246; COMPOUND E 564; COMPOUND E 565; COMPOUND E 567; COMPOUND E 673; COMPOUND E 692; COMPOUND E 721; COMPOUND E 728; COMPOUND E 729; COMPOUND E 804; COMPOUND E 805; COMPOUND E 806; INDIRUBIN; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; STAT5A PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL STRAIN K 562; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84862820219     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.02.002     Document Type: Article

References (37)

1. Aichberger K.J., Mayerhofer M., Krauth M.T., Skvara H., Florian S., Sonneck K., Akgul C., Derdak S., Pickl W.F., Wacheck V., Selzer E., Monia B.P., Moriggl R., Valent P., Sillaber C. Identification of mcl-1 as a BCR/ABL-dependent, target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005, 105:3303-3311.
2. Benekli M., Baer M.R., Baumann H., Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101:2940-2954.
3. Bromann P.A., Korkaya H., Courtneidge S.A. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004, 23:7957-7968.
4. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
5. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8:945-954.
6. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 1996, 183:811-820.
7. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
8. Eisenbrand G., Hippe F., Jakobs S., Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J. Cancer Res. Clin. Oncol. 2004, 130:627-635.
9. Gesbert F., Griffin J.D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000, 96:2269-2276.
10. Haura E.B., Turkson J., Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2005, 2:315-324.
11. Herrington J., Smit L.S., Schwartz J., Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene 2000, 19:2585-2597.
12. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1999, 1:60-67.
13. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002, 99:3792-3800.
14. Horita M., Andreu E.J., Benito A., Arbona C., Sanz C., Benet I., Prosper F., Fernandez-Luna J.L. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. 2000, 191:977-984.
15. Huang M., Dorsey J.F., Epling-Burnette P.K., Nimmanapalli R., Landowski T.H., Mora L.B., Niu G., Sinibaldi D., Bai F., Kraker A., Yu H., Moscinski L., Wei S., Djeu J., Dalton W.S., Bhalla K., Loughran T.P., Wu J., Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002, 21:8804-8816.
16. Klejman A., Schreiner S.J., Nieborowska-Skorska M., Slupianek A., Wilson M., Smithgall T.E., Skorski T. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. Embo J. 2002, 21:5766-5774.
17. Konig H., Copland M., Chu S., Jove R., Holyoake T.L., Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008, 68:9624-9633.
18. Lionberger J.M., Wilson M.B., Smithgall T.E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase- defective Hck. J. Biol. Chem. 2000, 275:18581-18585.
19. Marko D., Schatzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., Eisenbrand G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 2001, 84:283-289.
20. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., Hippe F., Vatter S., Merz K.H., Eisenbrand G., Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102:5998-6003.
21. Nam S., Kim D., Cheng J.Q., Zhang S., Lee J.H., Buettner R., Mirosevich J., Lee F.Y., Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS- 354825), on human prostate cancer cells. Cancer Res. 2005, 65:9185-9189.
22. Nam S., Williams A., Vultur A., List A., Bhalla K., Smith D., Lee F.Y., Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 2007, 6:1400-1405.
23. Nelson E.A., Walker S.R., Li W., Liu X.S., Frank D.A. Identification of human STAT5-dependent gene regulatory elements based on interspecies homology. J. Biol. Chem. 2006, 281:26216-26224.
24. Nieborowska-Skorska M., Wasik M.A., Slupianek A., Salomoni P., Kitamura T., Calabretta B., Skorski T. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 1999, 189:1229-1242.
25. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
26. Ptasznik A., Nakata Y., Kalota A., Emerson S.G., Gewirtz A.M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. 2004, 10:1187-1189.
27. Quintas-Cardama A., Kantarjian H., Jones D., Nicaise C., O'Brien S., Giles F., Talpaz M., Cortes J. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109:497-499.
28. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
29. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase- mediated tumorigenesis. Oncogene 2004, 23:8017-8023.
30. Vougogiannopoulou K., Ferandin Y., Bettayeb K., Myrianthopoulos V., Lozach O., Fan Y., Johnson C.H., Magiatis P., Skaltsounis A.L., Mikros E., Meijer L. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. J. Med. Chem. 2008, 51:6421-6431.
31. Wilson M.B., Schreiner S.J., Choi H.J., Kamens J., Smithgall T.E. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr- Abl signal transduction and oncogenesis. Oncogene 2002, 21:8075-8088.
32. Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M., Donato N.J. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008, 111:3821-3829.
33. Xiao Z., Hao Y., Liu B., Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 2002, 43:1763-1768.
34. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
35. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
36. Yuan H., Wang Z., Gao C., Chen W., Huang Q., Yee J.K., Bhatia R. BCR- ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J. Biol. Chem. 2010, 285:5085-5096.
37. Zhou J., Bi C., Janakakumara J.V., Liu S.C., Chng W.J., Tay K.G., Poon L.F., Xie Z., Palaniyandi S., Yu H., Glaser K.B., Albert D.H., Davidsen S.K., Chen C.S. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009, 113:4052-4062.